{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:34Z","timestamp":1790352214598,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Medical Science Research Foundation of Zhejiang Province, China","award":["2024KY1252"],"award-info":[{"award-number":["2024KY1252"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03584-x","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:47:04Z","timestamp":1750236424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus"],"prefix":"10.1186","volume":"27","author":[{"given":"Xiaowei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"22","key":"3584_CR1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"3584_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40396","volume":"70","author":"S Karrar","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS. Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us. Arthritis & rheumatology (Hoboken, NJ). 2018;70(4):496\u2013507.","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"6","key":"3584_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, B\u00f6ltz S, Manger B, Mackensen A, Schett G. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"key":"3584_CR4","doi-asserted-by":"crossref","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, V\u00f6lkl S, Aigner M, Bozec A, Mackensen A, Grieshaber-Bouyer R, Schett G: CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, NJ) 2024; 76(4):497-504.","DOI":"10.1002\/art.42784"},{"key":"3584_CR5","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Urquiza JL, Romero-Bejar JL, Chami-Pe\u00f1a S, Suleiman-Martos N, Ca\u00f1adas-De la Fuente GA, Molina E, Riquelme-Gallego B: Efficacy and Safety of New B Cell-Targeted Biologic Agent for the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(14):4848.","DOI":"10.3390\/jcm12144848"},{"issue":"5","key":"3584_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263\u201375.","journal-title":"Semin Immunol"},{"issue":"13","key":"3584_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","volume":"10","author":"SA Marsters","year":"2000","unstructured":"Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current biology\u202f: CB. 2000;10(13):785\u20138.","journal-title":"Current biology : CB"},{"issue":"5537","key":"3584_CR8","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1126\/science.1061964","volume":"293","author":"B Schiemann","year":"2001","unstructured":"Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (New York, NY). 2001;293(5537):2111\u20134.","journal-title":"Science (New York, NY)"},{"issue":"6","key":"3584_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"4","key":"3584_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3584_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus. 2023;32(1):94\u2013100.","journal-title":"Lupus"},{"issue":"8","key":"3584_CR12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022;31(8):998\u20131006.","journal-title":"Lupus"},{"issue":"9","key":"3584_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3584_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, NJ). 2019;71(9):1400\u201312.","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"7","key":"3584_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/acr.23109","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Gladman DD, Su J, Urowitz MB. Defining Low Disease Activity in Systemic Lupus Erythematosus. Arthritis Care Res. 2017;69(7):997\u20131003.","journal-title":"Arthritis Care Res"},{"issue":"9","key":"3584_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143\u201351.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3584_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"3584_CR18","doi-asserted-by":"crossref","unstructured":"Ji L, Geng Y, Zhang X, Deng X, Song Z, Tan M, Tan Y, Qu C, Zhang Z. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept. MedComm (2020). 2024;5(4):e515.","DOI":"10.1002\/mco2.515"},{"key":"3584_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","volume":"40","author":"D Ramsk\u00f6ld","year":"2019","unstructured":"Ramsk\u00f6ld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mike\u0161 J, Achour A, Amara K, et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019;40:517\u201327.","journal-title":"EBioMedicine"},{"key":"3584_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.666971","volume":"12","author":"S Piantoni","year":"2021","unstructured":"Piantoni S, Regola F, Masneri S, Merletti M, Lowin T, Air\u00f2 P, Tincani A, Franceschini F, Andreoli L, Pongratz G. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF\/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. Front Pharmacol. 2021;12:666971.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3584_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/09612033221137249","volume":"32","author":"A Hirano","year":"2023","unstructured":"Hirano A, Fujioka K, Kida T, Omura S, Sofue H, Sakashita A, Sagawa T, Isoda Y, Kasahara A, Sagawa R, et al. Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus. Lupus. 2023;32(1):63\u201373.","journal-title":"Lupus"},{"key":"3584_CR22","doi-asserted-by":"crossref","unstructured":"Struemper H, Kurtinecz M, Edwards L, Freimuth WW, Roth DA, Stohl W: Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE. Lupus science & medicine. 2022;9(1):e000499","DOI":"10.1136\/lupus-2021-000499"},{"issue":"4","key":"3584_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3899\/jrheum.100214","volume":"38","author":"C Landolt-Marticorena","year":"2011","unstructured":"Landolt-Marticorena C, Wither R, Reich H, Herzenberg A, Scholey J, Gladman DD, Urowitz MB, Fortin PR, Wither J. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol. 2011;38(4):642\u201351.","journal-title":"J Rheumatol"},{"issue":"11","key":"3584_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/0961203319869468","volume":"28","author":"A Benitez","year":"2019","unstructured":"Benitez A, Torralba K, Ngo M, Salto LM, Choi KS, De Vera ME, Payne KJ. Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. Lupus. 2019;28(11):1337\u201343.","journal-title":"Lupus"},{"key":"3584_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaut.2019.05.002","volume":"102","author":"Y Dieudonn\u00e9","year":"2019","unstructured":"Dieudonn\u00e9 Y, Gies V, Guffroy A, Keime C, Bird AK, Liesveld J, Barnas JL, Poindron V, Douiri N, Soulas-Sprauel P, et al. Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. J Autoimmun. 2019;102:150\u20138.","journal-title":"J Autoimmun"},{"key":"3584_CR26","doi-asserted-by":"crossref","unstructured":"Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne-Steele M, Pan W, Yang Q, Han J, Lesser M, et al. Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI insight 2018;3(17):e122525.","DOI":"10.1172\/jci.insight.122525"},{"issue":"11","key":"3584_CR27","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","volume":"189","author":"O Winter","year":"2012","unstructured":"Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol. 2012;189(11):5105\u201311.","journal-title":"J Immunol."},{"issue":"4","key":"3584_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12(4):232\u201340.","journal-title":"Nat Rev Nephrol"},{"key":"3584_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756941","volume":"12","author":"T Walhelm","year":"2021","unstructured":"Walhelm T, Gunnarsson I, Heijke R, Leonard D, Trysberg E, Eriksson P, Sj\u00f6wall C. Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. Front Immunol. 2021;12: 756941.","journal-title":"Front Immunol"},{"issue":"12","key":"3584_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2020;383(12):1149\u201355.","journal-title":"N Engl J Med"},{"issue":"13","key":"3584_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111019","volume":"39","author":"E Sevdali","year":"2022","unstructured":"Sevdali E, Block V, Lataretu M, Li H, Smulski CR, Briem JS, Heitz Y, Fischer B, Ramirez NJ, Grimbacher B, et al. BAFFR activates PI3K\/AKT signaling in human naive but not in switched memory B cells through direct interactions with B cell antigen receptors. Cell Rep. 2022;39(13): 111019.","journal-title":"Cell Rep"},{"key":"3584_CR32","doi-asserted-by":"crossref","unstructured":"Parodis I, Gomez A, Lindblom J, Chow JW, Sj\u00f6wall C, Sciascia S, Gatto M. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab. Int J Mol Sci. 2022;23(22):13941.","DOI":"10.3390\/ijms232213941"},{"key":"3584_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.852162","volume":"9","author":"I Parodis","year":"2022","unstructured":"Parodis I, Gomez A, Lindblom J, Chow JW, Doria A, Gatto M. Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. Front Med. 2022;9: 852162.","journal-title":"Front Med"},{"issue":"1","key":"3584_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201\u201310.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3584_CR35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/psp4.12919","volume":"12","author":"R Dimelow","year":"2023","unstructured":"Dimelow R, Gillespie WR, van Maurik A. Population model-based analysis of the memory B-cell response following belimumab therapy in the treatment of systemic lupus erythematosus. CPT Pharmacometrics Syst Pharmacol. 2023;12(4):462\u201373.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"3584_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fmed.2020.00085","volume":"7","author":"X You","year":"2020","unstructured":"You X, Zhang R, Shao M, He J, Chen J, Liu J, Zhang X, Liu X, Jia R, Sun X, et al. Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission. Front Med. 2020;7:85.","journal-title":"Front Med"},{"issue":"5","key":"3584_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41590-024-01798-w","volume":"25","author":"HF Bradford","year":"2024","unstructured":"Bradford HF, McDonnell TCR, Stewart A, Skelton A, Ng J, Baig Z, Fraternali F, Dunn-Walters D, Isenberg DA, Khan AR, et al. Thioredoxin is a metabolic rheostat controlling regulatory B cells. Nat Immunol. 2024;25(5):873\u201385.","journal-title":"Nat Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03584-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:47:11Z","timestamp":1750236431000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03584-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3584"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03584-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University (approval number KY2021-197). Informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}